Expanded Range of COVID-19 Testing Methods for Clinical Trials Announced
Press Article
Laboratorium für Klinische Forschung, a member of GBA Group Pharma, is offering an analytical method for detecting SARS-CoV-2 from nasopharyngeal swabs. This has enabled the company to significantly expand its existing range of COVID-19 testing methods for clinical trials. Based on a Roche LightCycler 480 II, which uses the technique of real-time PCR (polymerase chain reaction), LKF can now perform numerous molecular biological applications (DNA or RNA analyses). The detection of the RNA of the SARS-CoV-2 virus is a prerequisite for the diagnosis of an acute infection with the new corona virus causing the disease COVID-19.
published in LABMATE on the 1st June 2020